Utebzi: US approves antibiotic to treat urinary tract infections
Key takeaways
- The approval of the oral antibiotic, branded as Utebzi, offers a more convenient way to treat complicated infections—including a type of kidney inflammation called pyelonephritis—at home instead of in a hospital.
- While simple UTIs respond well to outpatient antibiotics, complicated UTIs carry a higher risk of treatment failure and can sometimes be fatal.
- GSK said the drug is expected to be available to U.S. patients by the end of 2026.
Why this matters: local context for readers following news across Pakistan and the region.
Add ARY News on Google AAResize The US FDA has approved GSK’s oral antibiotic Utebzi to treat complicated urinary tract infections, the regulator said on Wednesday, giving patients a new treatment option against drug-resistant infections.
The approval of the oral antibiotic, branded as Utebzi, offers a more convenient way to treat complicated infections—including a type of kidney inflammation called pyelonephritis—at home instead of in a hospital.
While simple UTIs respond well to outpatient antibiotics, complicated UTIs carry a higher risk of treatment failure and can sometimes be fatal. Complicated UTIs affect more than 2.8 million people in the United States each year.